Drug intelligence / Profile preview

Berbemor

Development stage: Unknown
Lead developer: Wellmora Pharma
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Berbemor is a multi-ingredient nutraceutical tablet formulated for women's daily nutritional, metabolic, and reproductive support. It contains a combination of Berberine HCl, Myo-inositol, D-chiro-inositol, Coenzyme Q10 (CoQ10), L-Methylfolate, Chromium, and Vitamin D3. The formulation is designed to support healthy blood sugar levels, insulin sensitivity, ovarian function, and hormonal balance, making it particularly beneficial for managing conditions like polycystic ovary syndrome (PCOS).

Brand names: BerbemorBerbemor TabletsBerbemor Women Tablet

Targets

AMPK (Adenosine monophosphate–activated protein kinase)INSR (Insulin receptor)

Beyond the preview

Go deeper on Berbemor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Berbemor.

Explore the full profile